The company's FDA-cleared wearable uses personalized nerve stimulation to treat essential tremor and Parkinson's disease.

Cala®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ® Plus system, the next-generation of its wearable neurostimulation device ...

The funds from Trinity Capital are expected to advance commercialisation efforts for Cala Health’s device for alleviating tremors in Parkinson’s and essential tremor patients.

Cala announced today that it received FDA clearance for its kIQ Plus next-generation wearable neurostimulation device.

For more than 200 years, Parkinson’s disease has been treated as a one‑way street, with drugs and devices that ease symptoms but do not truly repair the brain. That assumption is now under direct ...

Parkinson’s disease ranks second among the most common age-related neurodegenerative brain diseases. Alzheimer’s is first.

Combining medication with physical therapy in the early stages of Parkinson’s disease can significantly slow its progression, according to ...

Patty Gille started experiencing symptoms that affected her daily life, and she immediately felt something was off. “My legs ...